Afexa Life Sciences Inc.

Afexa Life Sciences Inc.

April 01, 2009 10:39 ET

COLD-FX® Maker Changes Company Name to Afexa Life Sciences Inc. as Part of Rebranding Plan

EDMONTON, ALBERTA--(Marketwire - April 1, 2009) - CV Technologies (TSX:CVQ) today announced that it is changing the Company's name to Afexa Life Sciences Inc. as part of a broader rebranding plan. The change was approved by shareholders at the Company's Annual General Meeting in Edmonton last week and takes effect today, following the filing of the Articles of Amendment. The ticker symbol under which the Company's common shares trade on the Toronto Stock Exchange (TSX) is also changing from CVQ to FXA. The Company expects that the common shares will commence trading under the new name and ticker symbol over the next two to three business days.

Company Executive Chair Jack Moffatt described the name change as a significant moment in the Company's history and signals its continuing corporate revitalization and its positioning as an influential life sciences company on the threshold of a variety of exciting opportunities.

"The name "CV Technologies" did not convey our rigorous life sciences orientation, or support our plans to leverage our market leading product as we launch new ones. Drawing on the outstanding brand equity associated with COLD-FX, we have chosen the name - Afexa Life Sciences Inc."

Mr. Moffatt added, "We expect over time to benefit from a halo effect - extending some of the popularity and goodwill associated with COLD-FX and its status as Canada's # 1 selling cold and flu remedy to new products, which are being developed through the same scientific rigour and exacting clinical trial process we applied to our core brand. Afexa (and future product names) will all phonetically echo the '-FX' tagline conveying the Science and innovation we will use to enhance our position in the wellness and self-care marketplace."

The Afexa name will begin appearing on products starting this fall as part of a larger plan to change packaging and messaging which began several months ago. In addition, a new product launch, currently planned for later this year will reflect the new packaging.


Afexa Life Sciences Inc., founded in 1992, strives to transform people's lives to be healthier and happier by focusing on prevention and recovery through the use of evidence-based naturally-derived health products. The Company's lead product COLD-FX strengthens the immune system and is widely used as a leading over the counter remedy ("OTC") for helping to prevent and relieve cold and flu infections. On April 1, 2009, the Company changed its name from CV Technologies Inc. to Afexa Life Sciences Inc.

Forward Looking Statement

This news release contains certain forward-looking statements and information within the meaning of applicable securities laws, which reflect current expectations of the management of Afexa Life Sciences Inc. (the "Company") regarding future events or the Company's future performance, including, without limitation, statements relating to the timing and/or initiation of clinical trials, clinical trial results, the introduction of new products, associated regulatory clearances, economic or financial trends or expectations, financing, acceptance of the Company's products in the marketplace and the hiring or retention of personnel. Forward-looking statements are often, but not always, identified by the use of words such as "expect", "anticipate", "seek", "aim", "continue", "estimate", "objective", "ongoing", "may", "will", "would", "project", "predict", "potential", "could", "should", "might", "believe", "plan", "target", "intend" and similar expressions. All statements other than statements of historical fact contained in this news release may be forward-looking statements. The forward-looking information included in this news release does not guarantee future performance and should not be unduly relied upon. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information, including, without limitation, the impact of competition, consumer confidence and spending levels, general economic conditions, interest and currency exchange rates, unseasonable weather patterns, the cost and availability of capital and grants/funding, product development uncertainties and labour market challenges. The Company believes that the expectations and assumptions reflected in the forward-looking information contained in this news release are reasonable but no assurance can be given that these expectations and assumptions are correct or that that the results, performance or achievements expressed in, or implied by, forward-looking statements will occur, or if they do, that any benefits may be derived from them. The Company assumes no duty to update or revise forward looking information, except as may be required pursuant to applicable laws. All forward-looking information is expressly qualified in its entirety by this cautionary statement. Further information regarding risks and uncertainties relating to the Company and its securities can be found in the disclosure documents filed by the Company with the securities regulatory authorities, available at The Company claims exemption under U.S. SEC Rule 12g3-2(b).

Contact Information